864070-37-1
Chemical Structure
SGLT2-IN-1
- CAS No.: 864070-37-1
- Formula:C19H21ClO6
- Molecular Weight:380.82
IUPAC Name: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChIKey: ODQAIMBPQWETBE-FQBWVUSXSA-N
SMILES: O[C@H]1[C@H](C2=CC(CC3=CC=C(C=C3)O)=C(C=C2)Cl)O[C@@H]([C@H]([C@@H]1O)O)CO
Biological Activity: SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SGLT2-IN-1 | 99.82% | SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SGLT2-IN-1 (Standard) | ≥98% | SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lansdell MI, et al., Design and synthesis of fluorescent SGLT2 inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4944-7. [Content Brief]
- [2]. Xu B, Feng Y, et al. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011 Aug 1;21(15):4465-70. [Content Brief]
Keywords
